D CTV of 51.8 Gy and 85.0% for a D CTV of 50.3 Gy, respectively. The respective total control probabilities, P B values are 94.8% and 92.5%, whereas the corresponding total complication probabilities, P I values are 0.9% and 7.4%. For the R2 case, the average P 1 values are 89.4% for a D CTV of 48.9 Gy and 88.6% for a D CTV of 49.0 Gy, respectively. The respective P B values are 89.8% and 89.9%, whereas the corresponding P I values are 0.4% and 1.2%. For the R1 case, the average P 1 values are 86.1% for a D CTV of 49.2 Gy and 85.5% for a D CTV of 49.1 Gy, respectively. The respective P B values are 90.2% and 90.1%, whereas the corresponding P I values are 4.1% and 4.6%. The combined effects of positioning uncertainties and breathing can introduce a significant deviation between the planned and delivered dose distributions in lung in breast cancer radiotherapy. The positioning and breathing uncertainties do not affect much the dose distribution to the CTV. The simulated delivered dose distributions show larger lung complication probabilities than the treatment plans. This means that in clinical practice the true expected complications are underestimated. Radiation pneumonitis of Grade 1-2 is more frequent and any radiotherapy optimization should use this as a more clinically relevant endpoint.
Radiobiological Evaluation of Breast Cancer
Radiotherapy Accounting for the Effects of Patient Positioning and Breathing in Dose Delivery. A Meta Analysis www.tcrt.org DOI: 10.7785/tcrt.2012.500274 In breast cancer radiotherapy, significant discrepancies in dose delivery can contribute to underdosage of the tumor or overdosage of normal tissue, which is potentially related to a reduction of local tumor control and an increase of side effects. To study the impact of these factors in breast cancer radiotherapy, a meta analysis of the clinical data reported by Mavroidis et al. (2002) in Acta Oncol (41:471-85) , showing the patient setup and breathing uncertainties characterizing three different irradiation techniques, were employed. The uncertainties in dose delivery are simulated based on fifteen breast cancer patients (5 mastectomized, 5 resected with negative node involvement (R2) and 5 resected with positive node involvement (R1)), who were treated by three different irradiation techniques, respectively.
The positioning and breathing effects were taken into consideration in the determination of the real dose distributions delivered to the CTV and lung in each patient. The combined frequency distributions of the positioning and breathing distributions were obtained by convolution. For each patient the effectiveness of the dose distribution applied is calculated by the Poisson and relative seriality models and a set of parameters that describe the doseresponse relations of the target and lung. The three representative radiation techniques are compared based on radiobiological measures by using the complication-free tumor control probability, P 1 and the biologically effective uniform dose, D concepts. For the Mastectomy case, the average P 1 values of the planned and delivered dose distributions are 93.8% for a
Introduction
Radiation therapy is usually used as the treatment of choice for breast cancer cases. A long disease-free treatment outcome is needed in order to characterize a given breast cancer radiotherapy as successful. It has been shown in randomized cases that radiotherapy significantly reduces locoregional recurrence opposed to operative treatment (1) . This happens when radiotherapy treatment is applied after breast conserving surgery (resection) of removal of the whole breast (radical mastectomy) (2, 3) . Nowadays, the application of radiation therapy after surgery is frequently used to decrease local relapse in the breast (4-6). Breast cancer radiotherapy is used to decrease the relapse rate reducing at the same time the side effects, thus improving the trade-off between benefits and complications from the treatment (1, 7) .
The precision of the quality control process provides us the capability to identify the potential sources of errors during a treatment planning process, thus influencing the clinical results of radiotherapy. Accuracy in patient positioning is a prerequisite to ensure agreement between the planned and delivered dose distributions to the patient (8) (9) (10) (11) . Local tumor control may be reduced due to variations in dose distribution and in dose delivery. These variations stem from the patient setup and organ motion inaccuracies, which can produce deviation of the delivered dose distribution as opposed to the calculated CT-based treatment plan and the effect in the dose-volume histograms can be considerable (12) (13) (14) (15) . These situations can potentially lead to underdosage of the tumor or overdosage of normal tissues thus increasing the side effects.
To identify localization errors in patient setup, portal films or electronic portal imaging devices have long been used for the verification of field alignment (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) .
Three groups of patients, who correspond to Mastectomized patients and patients having undergone breast-conserving surgery, were employed in order to analyze the influence of positioning and breathing uncertainties in breast cancer radiotherapy. The deviation between the planned and delivered dose distributions that occur due to these uncertainties is calculated by comparing the corresponding dose volume histograms of the CTV and ipsilateral lung. These differences in the dose distributions affect the predicted response probabilities and the effectiveness of the corresponding treatment plans.
The estimation of the effectiveness of a dose distribution can be a challenging task due to the lack of important clinical data that affect the response of each individual tissue. Isodose charts, dose volume histograms (DVH), dosevolume points and conformity based indices are currently used for treatment plan evaluation. However, all these evaluation measures are only dose based and they do not take the radiobiological characteristics of tumours or normal tissues into account. Consequently, radiobiological measures have to be also employed in order to estimate the response of the different tissues and the overall expected treatment outcome. To analyze competing dose distributions, the use of the biologically effective uniform dose (D ) and complication-free tumor control (P 1 ) have been proposed as alternative tools for radiotherapy treatment plan evaluation (26). The biologically effective uniform dose, D concept assumes that different dose distributions are equivalent when causing the same probability for tumor control or normal tissue complication (27). By applying these radiobiological measures, the effectiveness of the planned and delivered dose distributions are investigated for 15 breast cancer patients.
Methods and Materials

Patients
This study is a meta analysis of the work by Mavroidis et al. (2002) in Acta Oncol (41:471-85) (28). From the patient population of 60 breast cancer patients that were involved in that study, fifteen patients treated with radiotherapy for breast cancer between 1996 and 1998 at the Tampere University Hospital were selected on the ground that the additional clinical data, needed for the present study, were available. Among these patients, 5 patients had mastectomy (M), whereas 10 of them underwent breast conservation (resection). For the treatment of the mastectomized patients, two opposite anterior-posterior photon fields for irradiating the regional lymph node areas and one electron field for irradiating the chest wall and parasternal lymph node areas, were applied (Figure 1, upper) . From the latter group of patients, 5 had negative local lymph node involvement (R2). These patients were treated postoperatively with two nearly opposed tangential 6 MV photon wedge fields (Figure 1 , middle). The remaining 5 resected patients had positive lymph node involvement (R1), which was treated by adding one frontal photon field to the tangential fields mentioned above (Figure 1, lower) . The patients started radiotherapy 4-8 weeks after surgery. During CT acquisition the patients were lying in supine position with both of their arms abducted from the body above the head.
In the mastectomized patients, the CTV contained the chest wall and the regional lymph node areas (axillary, supraclavicular and parasternal). In the resected negative-node patients, the CTV included the whole breast containing the fatty tissue and skin. In the resected positive-node patients, the CTV contained additionally the thoracic wall, the ipsilateral internal mammary and axillary and supra-clavicular lymph nodes. The planning target volume (PTV) was formed by adding a margin of 9-14 mm to the CTV depending on the directions of the setup errors and breathing.
The prescribed total radiation dose was 50 Gy, given in five fractions per week at a daily dose of 2 Gy. A 3D treatment planning system (CADPLAN, Varian Associates Inc.) was used to perform the delineation of the involved structures and dose calculation. Inhomogeneity correction was performed during the calculation of the dose distribution in the lungs. The DVHs were calculated for the CTV and the ipsilateral lung. For the three groups of patients, a representative total view of the field geometries and patient anatomies is depicted in Figure 1 .
Simulation of 'Effective' Fields by Combining Positioning Uncertainties and Breathing Effects
A Gaussian distribution was used in each direction to simulate the corresponding positioning uncertainties due to the random nature of the setup errors. Positioning uncertainties reported in the literature were used for the anterior-posterior and cranial-caudal directions (8-10, 12, 21) . The lateral positioning uncertainty was not accounted for in this study. The Gaussian distributions are produced by using the average standard deviation values in the anterior-posterior (3.4 mm) and cranial-caudal (5.8 mm) directions, that have been reported (28). The Gaussian distributions were integrated over the intervals (2∞, 22.5; 22.5, 12.5; 12.5, 1∞ ) (in mm) in the AP direction and over the intervals (2∞, 23.5; 23.5, 13.5; 13.5, 1∞) in the CC direction in order to calculate the positions and the weights of these bins.
In order to estimate the combined effect of the breathing and positioning uncertainties, the overall uncertainty could be calculated as a convolution of the two distribution functions (14, 21) . The combined distribution of the positioning and breathing uncertainties in the AP and CC directions is depicted in the upper diagrams of Figure 2 , respectively. A 3-dimensional histogram can be used to simulate this distribution whose bins describe the various fields that could replace the fields of original treatment plan in an attempt to simulate the clinical situation. The positions and the heights of these histogram bins are described by arrows that correspond to the positions and the weights of the simulating fields in the lower diagrams of Figure 2 .
Radiobiological Measures for Treatment Plan Evaluation
The response probability of lung to a non-uniform dose distribution (  D) is given by the relative seriality model, which also accounts for its volume effect (28-30):
where N is the total number of voxels or subvolumes in lung, Δv i = ΔV i / V ref is the fractional subvolume of the organ (ΔV i ) that is irradiated at the dose level D i compared to the reference volume (V ref ) for which the values of the model parameters have been determined. D 50 is the dose that gives a response probability of 50%, γ is the maximum normalized value of the dose response gradient and s is the relative seriality parameter that characterizes the internal organization of lung. The parameters D 50 and γ and s are specific for every organ and type of injury (clinical endpoint) and they can only be derived from clinical data.
Each lung dose distribution was corrected using the linearquadratic model to a 2 Gy per fraction schedule. Thus, each dose step in the histograms was corrected separately. The α /β value assumed in the fractionation correction was 3.0 Gy.
In targets, the structural organization is assumed to be parallel since the eradication of all their clonogenic cells is required. Taking this feature into account the overall probability of benefit P B is given by the expression:
In Table I , the dose-response parameters of the organs involved in this study are shown and are based on published data (31-35). The D 50 , γ and s parameters describe the shape of the dose-response curve, which subjects to uncertainties such as the inter-patient and intra-patient variation of radiosensitivity, setup uncertainties, accuracy of the radiobiological model etc. In this study, it was assumed that the patients are of average radiosensitivity.
The biologically effective uniform dose, D , is defined as the dose that causes the same tumor control or normal tissue complication probability as the actual dose distribution delivered to the patient (27). The general expression of D is derived numerically by the first part of the following equation, whereas for a tissue of uniform radiosensitivity, D is given from the analytical formula of the second part:
where  D denotes the 3-dimensional dose distribution delivered to the tissue and P D ( )  is the response probability of the tissue. The second part of the equation has been derived using the Poisson model. P 1 is a scalar quantity, which expresses the probability of achieving tumor control without causing severe damage to normal tissues (26). In this work, the probability of getting benefit from a treatment (total tumor control) is denoted by P B , whereas the probability for causing severe injury to normal tissues by P I . Using these quantities, P 1 can be estimated from the following expression:
In this study, to evaluate the effectiveness of the different treatment plans, conventional physical criteria like dose volume histograms, dose volume constraints, mean doses and dose variations in the target volumes and organs at risk were used together with the respective minimum and maximum doses and the radiobiological indices D and P 1 .
In the P 1 vs. D diagrams, in every prescription dose, the average response probabilities are calculated and plotted for every treatment technique. In these diagrams, the doseresponse curves have been normalized to the D B , which forces the response curves of the CTV (P B ) of the different treatment plans to coincide. The normalization using D B allows the inter-comparison of the different modalities on the same basis and gives emphasis to the therapeutic window, which characterizes each treatment plan.
Results
For the treatment plans of the Mastectomized patients, the average prescribed mean dose to the CTV is 53.1 Gy, whereas in the delivered plans it is 51.7 Gy (Table II) (Table V) .
In the R2 case, the average prescribed mean dose to the CTV is 49.2 Gy in both the planned and delivered dose distributions (Table III) (Table V) .
For the R1 treatment plans, the average prescribed mean dose to the CTV is 49.6 Gy, whereas in the delivered plans it is 49.5 Gy (Table IV) . The corresponding average maximum and minimum doses are 52.8 Gy and 45.0 Gy for the planned dose distributions and 52.6 Gy and 45.2 Gy for the delivered dose distributions, respectively. For lung, the average mean, maximum and minimum doses are 12.9 Gy, 51.0 Gy and 0.7 Gy for the planned dose distributions and 15.1 Gy, 50.9 Gy and 0.6 Gy for the delivered dose distributions. For the two series of dose distributions, the P 1 values are 86.1% Table II . Table II Summary of the dosimetric and radiobiological measures averaged over the 5 mastectomized breast cancer patients. The absolute values refer to the treatment plans, whereas the differences express the deviations of the delivered dose distributions from the planned ones. The quantities D mean , D max , D min and SD refer to the average, maximum, minimum and standard deviation of the corresponding dose distributions. The values of the quantities are given in terms of the average 6 standard deviation values over that patient group. (Table V) .
The dose volume histograms (DVHs) of the CTV and ipsilateral lung were computed for each of the fifteen patients. Figure  3 shows the mean, higher and lower cumulative dose-volume histograms (planned and delivered) for the three groups of patients (Mastectomy, R2 and R1). The difference of the corresponding histograms illustrates the average changes in the delivered dose distribution imposed by the positioning uncertainties and breathing effects. Based on the DVHs it is observed that for the CTV the differences between the planned and delivered dose distributions are small. Regarding the ipsilateral lung this holds only for the R2 case. In the Mastectomized patients the delivered DVHs are considerably higher than the planned ones, whereas in the R1 case the difference is smaller but still considerable.
Following the calculation of the biologically effective uniform dose, D for the different cases, it is found that the average effective dose difference in the Mastectomy case is 1.5 Gy for CTV and 5.8 Gy for lung. In the R2 case, the differences are 0.1 Gy and 0.7 Gy, respectively, whereas in the R1 case the respective differences are 0.1 Gy and 1.8 Gy.
In Figures 4-6 , the average dose-response curves of the CTV (P B ), ipsilateral lung (P I ) and P 1 are shown for different prescription doses for the Mastectomized, R2 and R1 patient groups. The comparison between the planned and delivered dose distribution shows that in the Mastectomized patients the actually delivered dose distributions were characterized by a lower effectiveness than the planned ones ( Figure 4 ). In the R2 case, the effectiveness of the planned dose distribution was slightly higher at all the clinically prescribed dose levels. If a more sensitive clinical endpoint is used for lung then the planned dose distribution seems to spare lung better, which results in a higher overall effectiveness for the treatment plans ( Figure 5 ). In the R1 case, the pattern of findings observed for the Mastectomized patients is repeated but less pronounced with the planned dose distributions giving higher P 1 values than the delivered ones ( Figure 6 ). However, when radiation pneumonitis Grade 1-2 was used instead as the clinical endpoint, then the effectiveness of the difference in the effectiveness between the planned and delivered dose distributions became much larger.
In Figure 7 , the individual response probabilities of the CTV, ipsilateral lung and P 1 are presented for the planned and delivered dose distributions of the Mastectomized, R2 and R1 patients. In these histograms it can be observed that there are variations in the results between the different groups of patients but also among the patients of the same group.
Discussion
Radiation therapy outcome depends heavily on the quality control of the treatment because there are many possible sources of errors. These errors that occur during the delivery of the treatment to the patient have as a result the degradation of the curative power and effectiveness of the treatment (36). In breast cancer radiotherapy, such sources of errors are the positioning uncertainties and the breathing effects and they may lead to a dose delivery that is different to the one intended originally to be given (37). In external radiotherapy, the geometry of the patient setup must be kept identical between treatment plan and during all the delivered treatment fractions. If this request is not satisfied, the delivered dose to the patient will differ from the planned one having as a consequence the treatment result to be different from the expected one (38, 39) .
The present study verifies that the combined effects of positioning uncertainties and breathing motion can introduce a considerable deviation between the planned and delivered dose distributions in breast cancer radiotherapy. The influence of the deviation between the planned and delivered dose distributions on the clinical outcome may be estimated by using radiobiological measures. In this work, the radiosensitivity of lung was assumed to be uniform although there are reports indicating that its radiosensitivity may vary within its volume, which may have a considerable impact on the calculation of the expected response probability.
The radiobiological parameters that are used in the present manuscript have been derived from clinical trials and they are characterized by confidence intervals. In the calculations of the study, we have used the best estimates of the parameter values, which are relevant to the majority of the patients to be examined. The parameter confidence intervals stem from lack of knowledge such as the inter-patient radiosensitivity, agreement between the treatment and delivered dose distribution, radiobiological model deficiencies, inclusion of further biological mechanisms that take place during the process of therapy and affect the final result etc. The use of a different set of parameter values for the corresponding confidence intervals will change the absolute values of the corresponding response probabilities but will not change the pattern of the observed results. Furthermore, in some studies, it has been noticed that for an organ have been used parameter values that have been derived for another part of that organ than the one for which they are applied (e.g. thoracic part of esophagus against proximal esophagus or thoracic part of spinal cord against cervical part of spinal cord) (40, 41). However, this issue does not hold for the The sample of the examined 15 patients was extracted from a larger patient population of 120 patients, who received radiotherapy. Among the group of the 120 patients, 9 showed radiation pneumonitis of Grade 2 and 53 showed radiation pneumonitis of Grade 1 and 2. For the group of the examined 15 patients, the planned and delivered response rates that were predicted for Grade 2 radiation pneumonitis as well as the clinically registered response rate are 1.8%, 4.4% and 7.5%, respectively. The corresponding values for Grades 1 and 2 radiation pneumonitis are 24.0%, 39.3% and 44.2%, respectively. These results indicate that the simulated delivered response rates are much closer to the clinical response rates of the whole patient population than the planned response rates.
The differences between the predicted and clinical response rates stem from the fact that the fifteen patients that were selected may not represent the group of 120 patient in all aspects and that the radiobiological parameters that were used were not derived from this patient population, which means that they may need some adjustment in order to reproduce the response pattern of this population with a higher accuracy.
It has to be stated that for the clinical endpoint of Grade 2 radiation pneumonitis after breast cancer irradiation, diverging response rates have been published. Most groups have reported complication rates of the order of 0-2% (42, 43). However, much higher incidences that range between 5 to 25% have also been reported (35, 42, 44) . It seems that the response of radiation pneumonitis strongly depends on the irradiation techniques applied, which usually involve multiple photon and electron fields.
The delivered treatment plans show larger lung complication probabilities than the original plans in the Mastectomy, R2 and R1 cases. This means that the true expected complications are often underestimated in clinical practice. Presently, the highly conformal dose distributions that are produced by the more sophisticated radiotherapy units very rarely produce severe lung complication in breast cancer radiotherapy. So, the use of radiation pneumonitis of Grade 2 or higher seems to be of low clinical relevance. Instead, radiation pneumonitis of Grade 1 and 2 is more frequent and any radiotherapy optimization should use this as a more clinically relevant endpoint (45).
In Figure 3 , it is shown that the positioning and breathing uncertainties do not affect much the dose distribution to the CTV. This was expected since the uncertainties studied influence more the tissues lying at the edges of the irradiating fields, whereas the CTV, which is in the interior part of the PTV (CTV-PTV margins account for the setup uncertainties) seems to be completely irradiated with the planned prescribed dose.
According to the findings of the study, the influence of the positioning uncertainties and breathing effects on the delivered dose distribution relies on the geometrical relationship of the treatment fields and the patient. This deviation in the dose distribution between the planned and delivered dose distributions on the clinical outcome may be estimated by using radiobiological models and the biologically effective uniform dose concept. The linear-quadratic-Poisson and relative seriality models were employed to estimate the expected tumor control and lung complication probabilities. The individual dosimetric information of the planned and the delivered dose volume histograms were used in all the three treatment cases. Based on this data, the computed lung response probability was higher for the delivered dose distributions compared to the original plans in the Mastectomy R2 and R1 techniques. The meaning of this finding is that the expected complications were underestimated during the initial radiobiological evaluation of the treatment plans.
The effectiveness of a given dose distribution is evaluated by the comparison of its advantages in terms of tumor control against its disadvantages regarding normal tissue complications (46). The original definition of P 1 does not use different weights for the targets and OARs as well as different weights for the different normal tissues. In clinical practice, there are not different weighting factors that are applied but there are risk thresholds (usually 5-10%) for every organ at risk, which should not be exceeded. So, in order to classify the different treatment plans one can select in the diagrams of Figures 4-6 the dose level that satisfies the demands imposed by the normal tissues risk thresholds and associate them with the expected tumor control rate at this dose level.
Biologically effective uniform dose has mainly been used in Figures 4-6. In order to plot the response probabilities of the different targets and OARs against the dose distribution that is delivered by a treatment plan, a single dose it is needed that is as iso-effective as the 3-dimensional dose distribution of the plan. The original expression of equivalent uniform dose (EUD) has such a characteristic regarding the survival of the tumor and for the Poisson model that has been used in the present study, the EUD for the tumor could also be used but not for the OARs (47). On the other hand, the generalized equivalent uniform dose (gEUD) concept does not have a direct relation with the response of a tissue (48). In this way, the monotonous relationship of gEUD-response that is needed in order to make iso-effectiveness comparisons and equivalent dose-response plots for different treatment plans does not exist in the concept of gEUD. However, if appropriate alpha values could be used, the corresponding gEUD values should be close to the ones that the biologically effective uniform dose calculated. In the present study, the authors could not perform such an analysis because the literature found alpha values, which are used to calculate the corresponding gEUDs, should be compatible with the parameter values of the radiobiological models. Such a type of compatibility test requires the availability of a different clinical material than the one used in the present study in order to be performed.
The values of the positioning uncertainties and the breathing displacement used in this work were retrieved from the literature. These values were clinically estimated to be in close proximity to the ones associated with the examined treatment techniques. The most appropriate way to perform this study would be to estimate these uncertainty values from the same patient material using portal imaging or other treatment verification means. However, this would be necessary if the goal of the study was to associate the dosimetric findings with true treatment outcome data. Since such data are not available, the present study tries to estimate the magnitude of deviation that should be expected in the clinical outcome due to the discrepancies between the planned and delivered dose distributions.
The radiobiological parameter values applied to a certain patient material should be compatible with this patient material. These parameters are extracted from patient materials where the dose delivered to each patient and the follow-up records are available. The values of the parameters are influenced by the variation of the treatment methodologies among different institutions and the limitations in the clinical information used such as imaging at cellular level, accurate determination of the dose delivered to the patient, radiosensitivity of the individual patient etc. (49). By using a set of published radiobiological parameters, the order of the relative difference in the effectiveness between the planned and delivered dose distributions could be estimated in terms of treatment outcome. However, by examining the treatment methodology applied for the derivation of the parameters and the study material it was realized that the values of these radiobiological parameters need to be adjusted in order to be fully compatible with the present patient population and be used clinically.
Conclusions
The difference between planned and the delivered dose distributions in breast cancer radiotherapy can be significantly influenced by the combined effects of positioning uncertainties and breathing. This difference can introduce significant differences in the effectiveness of the corresponding dose distributions and consequently in the expected treatment outcome. In the presented Mastectomy, R2 and R1 treatment configurations a higher rate of lung radiation pneumonitis (Grade 2) are predicted by the delivered compared to the planned dose distributions, which is supported by the clinical follow-up results. The same pattern of results are observed when using radiation pneumonitis of Grades 1 and 2, which is a more frequent type of lung complication and a more clinically relevant endpoint for treatment plan comparison and breast cancer radiotherapy optimization. In the absence of a modern treatment delivery technology such as gating, one way to deal with those effects is to perform a simulation of the true dose delivery by applying a number of fields of various weights and entry points during the process of treatment planning. Ågren et al. as well as Löf et al. have described the statistical background of the complication free tumor control probability concept (50, 51). In general, complication free tumor control probability (P 1 ), may be expressed by the tumor control probability minus the probability that the patients are controlled, but nevertheless still suffer injury:
where B and I stand for benefit (or control) and injury, respectively, whereas P I∩B is the probability of having both injury and benefit. This equation may be rewritten as:
where P I|B is the probability of having injury while there is benefit. Only a small fraction of the patients are statistically independent when the tumor and normal tissues are uniformly irradiated (50). In this case the probability of having net benefit from a treatment is:
When injury and control are completely correlated, which in most cases is a valid assumption, complication free tumor control will be given by:
